

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

SUPERIOR COURT OF THE STATE OF CALIFORNIA  
FOR THE COUNTY OF LOS ANGELES

KATHERINE LEE BUCKLAND, *et al.*,

Plaintiffs,

v.

THRESHOLD ENTERPRISES, LTD., *et al.*

Defendants.

Case No. BC344046  
[Hon. Robert L. Hess]

**[PROPOSED] CONSENT  
JUDGMENT ONLY AS TO  
DEFENDANTS  
LIFE-FLO HEALTH CARE  
PRODUCTS, INC.;  
ALLVIA INTEGRATIVE  
PHARMACEUTICALS, INC.; AND  
SAYGE BIOSCIENCES LLC**

Complaint Filed: December 7, 2005  
Location: Dept. 24, Room 314

This Consent Judgment is entered into by and between Katherine Lee Buckland ("Ms. Buckland"), the California Women's Law Center ("CWLC" – collectively with Ms. Buckland, "Plaintiffs"), and defendants Life-Flo Health Care Products, Inc., Allvia Integrative Pharmaceuticals, Inc., and Sayge Biosciences LLC (hereinafter "Defendants"). Plaintiffs and Defendants may be collectively referred to herein as "Parties."

1. **Definitions.** As used in this Consent Judgment, the following definitions shall apply:

1.1 "Regulated Chemicals" are: Progesterone, Medroxyprogesterone acetate, Testosterone and its esters, Methyltestosterone, Testosterone cypionate, and/or Testosterone enanthate as an ingredient. Each Regulated Chemical is a chemical known to the State of



1 Drinking Water and Toxic Enforcement Act of 1986, California Health and Safety Code §  
2 25249.5 et seq. ("Proposition 65"); Title 22, California Code of Regulations § 12000 et seq.

3       **2.4** On or about July 28, 2005, CWLC served Defendants and each of the appropriate  
4 public enforcement agencies with a "60-Day Notice" that provided Defendant and the public  
5 enforcement agencies with a notice alleging that Defendant was in violation of Proposition 65  
6 for failing to warn the purchasers of, and individuals using, the Products that the use of the  
7 Products exposes them to Regulated Chemicals. Defendants stipulate for the purpose of this  
8 Consent Judgment that the 60-Day Notice sent to them is adequate to comply with Title 22,  
9 California Code of Regulations §12903. None of the public enforcement agencies has  
10 commenced and begun diligently prosecuting an action against Defendants for such alleged  
11 violations.

12       **2.5** On or about October 5, 2005, Ms. Buckland, pursuant to Civil Code § 1782 served  
13 Defendants with a notice letter (the "CLRA Notice" -- collectively with the 60-Day Notice,  
14 "Notices") via certified mail, return receipt requested, stating *inter alia* as follows:

15               These Products have been sold to literally millions of California  
16 consumers without any of the noticed companies providing a clear  
17 and reasonable warning prior to their purchase by a consumer that  
18 the Progesterone, Medroxyprogesterone acetate, Testosterone and  
19 its esters, Methyltestosterone, Testosterone cypionate, and/or  
20 Testosterone enanthate in these Products are chemicals known to be  
21 carcinogens and/or reproductive toxins by the State of California.  
22 Nor has any of the noticed companies disclosed the potential  
23 adverse health effect risks posed by exposure to these chemicals in  
24 these Products because Progesterone, Medroxyprogesterone acetate,  
25 Testosterone and its esters, Methyltestosterone, Testosterone  
26 cypionate, and/or Testosterone enanthate in these Products are  
27 chemicals regulated as drugs by the U.S. Food and Drug  
28 Administration under the federal Food, Drug and Cosmetic Act.  
These omissions of material facts constitute deceptive  
representations and misrepresentations, failure to disclose that the  
product is a regulated drug, and misbranding in violation of § 1770  
of the CLRA.

25       **2.6** On December 7, 2005, Ms. Buckland and CWLC filed their initial complaint  
26 entitled *Buckland, et al. v. Threshold Enterprises, Ltd., et al.*, No. BC344046, in the Los Angeles  
27 County Superior Court. On January 24, 2006, Plaintiffs filed their First Amended First  
28 Amended. Ms. Buckland alleged violations of the CLRA, Business & Professions Code

1 §§ 17200 *et seq.* and 17500 *et seq.*, and Civil Code §§ 1709 and 1710, against Defendants. Ms.  
2 Buckland alleged no claim, directly or indirectly, pursuant to Proposition 65 (H&S Code  
3 § 25249.5 *et seq.*) in the First Amended Complaint. CWLC alleged violations of Proposition 65  
4 (H&S Code § 25249.5 *et seq.*) in the First Amended Complaint against Defendants. On August  
5 21, 2006, Ms. Buckland filed a Supplemental Complaint. On November 6, 2006, CWLC filed a  
6 Second Amended Complaint and Ms. Buckland filed a First Amended Supplemental Complaint  
7 (collectively "Complaints").

8       **2.7** For purposes of this Consent Judgment only, the Parties stipulate that this Court  
9 has jurisdiction over the allegations of the violations contained in the Notices and the  
10 Complaints, and personal jurisdiction over Defendants as to the acts or omissions alleged in the  
11 Complaints; that venue is proper in the County of Los Angeles; and that this Court has  
12 jurisdiction to enter this Consent Judgment.

13       **2.8** Defendants deny that the Products have been or are in violation of any law, and  
14 further contend that all Products have been and are safe for use as directed. However, the Parties  
15 desire to resolve this matter (including the Notices, Complaints and all related matters) without  
16 further litigation or cost.

17       **2.9** The Parties enter into this Consent Judgment to settle certain disputed claims as  
18 alleged in the Notice and the Complaints, to avoid prolonged and costly litigation, and to  
19 promote the public interest. By executing and complying with this Consent Judgment, no Party  
20 admits any facts or conclusions of law including, but not limited to, any facts or conclusions of  
21 law regarding any violations of the California Legal Remedies Act (Civil Code § 1750 *et seq.*),  
22 the Unlawful Competition Law (B&P Code § 17200 *et seq.*), the False Advertising Law (B&P  
23 Code § 17500 *et seq.*), Civil Code §§1709 and 1710, Proposition 65 (Health & Safety Code  
24 §25249.5 *et seq.*) or any other statutory, common law or equitable claim or requirement relating  
25 to or arising from Defendants' Products. This Consent Judgment shall not be construed as an  
26 admission by Defendants as to any of the allegations in the 60-Day Notice, the CLRA Notice, or  
27 the Complaints.

28 ///

1 **3. Injunctive Relief.**

2 **3.1 Future Product Sales Require a Warning.**

3 Pursuant to Civil Code § 1782(d), and B&P Code §§ 17203 and 17535, and Health &  
4 Safety Code §25249.7(a), the sale of a Product by Defendants to consumers in California shall  
5 be accompanied by a warning. This warning shall be provided both by (a) product labeling  
6 pursuant to Paragraph 3.1.1; and (b) warnings for any mail order and Internet sales pursuant to  
7 Paragraph 3.1.2.

8 **3.1.1 Product Label Warnings**

9 At the earliest such time when, in the ordinary course of business, new labels for the  
10 Products are printed on or after March 30, 2007, Defendants shall include: on the label of each  
11 of its Products that it manufactures and ships for sale into California, (in the same type size as  
12 the surrounding, non-heading text), the following warning, including the specific name or names  
13 of the Regulated Chemicals where shown:

14 “WARNING: This product contains [Progesterone,  
15 Medroxyprogesterone acetate, Testosterone and its esters,  
16 Methyltestosterone, Testosterone cypionate, and/or Testosterone  
17 enanthate], a chemical(s) known to the State of California to cause  
18 cancer. Consult with your physician before using this product.”

19 **3.1.2 Additional Warnings for Mail Order or Internet Sales**

20 If Defendants sell a Product by mail order or over the Internet to a consumer in the State  
21 of California on or after the date that is 90 days after the entry of this consent judgment by the  
22 court, the following additional requirements shall apply:

23 (1) For such mail order sales, the warning language required under this Consent  
24 Judgment at paragraph 3.1.1 shall be included in the mail order catalogue, either on the same  
25 page as any order form, or on the same page(s) upon which the Product’s price is listed, in the  
26 same type size as the surrounding, non-heading text.

27 (2) For such Internet sales, the warning language required under this Consent  
28 Judgment at paragraph 3.1.1 shall be displayed (in the same type size as the surrounding, non-

1 heading text) in one or more of the following ways: (a) on the same page upon which the  
2 Product is displayed or referenced; (b) on the same page as any order form for any Product; (c)  
3 on the same page as the price for the Product is displayed; (d) on one or more pages displayed to  
4 a purchaser over the Internet or via electronic mail during the checkout and order confirmation  
5 process for sale of a Product; or (e) in any manner such that it is likely to be read and understood  
6 by an ordinary individual under customary business conditions prior to the purchase of the  
7 Product.

8       **3.2** Pursuant to Civil Code § 1782(d) and B&P Code §§ 17203 and 17535, and Health  
9 & Safety Code §25249.7(a), and effective when, in the ordinary course of business, new labels  
10 and advertising, marketing, mail order catalog or Internet-based descriptions of each of its  
11 respective Products are printed or posted electronically on or after March 30, 2007, Defendants  
12 agree to remove any “therapeutic” claims (as that term is used by the U.S. Food and Drug  
13 Administration under Title 21 United States Code § 321(g) and Title 21 Code of Federal  
14 Regulation, Part 310.530, Over-The-Counter Topically Applied Hormone Drug Products) made  
15 by Defendants for any of its respective Products.

16 **4. Financial Settlement.**

17       **4.1** In lieu of damages or penalties, Defendants shall pay to the CWLC the sum of  
18 \$15,000 (“Settlement Amount”), and shall make that payment to the Client Trust Account of the  
19 Carrick Law Group P.C., by wire transfer, certified or bank check in immediately available  
20 funds. This Settlement Amount shall be due and payable within five (5) calendar days after the  
21 date of notice of entry of this Consent Judgment. This Settlement Amount shall be disbursed  
22 promptly thereafter by the Carrick Law Group P.C. to the CWLC.

23 **5. Claims Covered and Released.**

24       This Consent Judgment includes the resolution of all actual and potential claims that were  
25 considered or could have been brought by Plaintiffs regarding the Regulated Chemical(s) in  
26 Defendants’ Products. This Consent Judgment is a final and binding resolution between  
27 Plaintiff and Defendants of any and all alleged violations of the CLRA, the Unfair Competition  
28 Law, the False Advertising Law, Civil Code §§1709 and 1710, Proposition 65, or any other law

1 that was or could have been asserted by Plaintiff arising from or related to Defendants' Products  
2 up through the date of entry of this Consent Judgment, including, but not limited to any claims  
3 for attorneys' fees and costs (collectively "Claims"). Plaintiffs hereby release the Defendants'  
4 Releasees (as defined below) and waive all rights to institute or participate in, directly or  
5 indirectly, any form of legal action seeking any form of relief (whether injunctive,  
6 compensatory, punitive, or otherwise) arising from the Claims against Defendants, their officers,  
7 directors, employees, agents, attorneys, consultants, representatives, shareholders, parents,  
8 subsidiaries, affiliates, divisions, predecessors, successors, subdivisions, downstream  
9 distributors, downstream retailers, downstream customers, and upstream suppliers of the raw  
10 materials used in the Products (the "Defendants' Releasees"); however, Plaintiffs cannot and  
11 expressly do not release any other claims, including specifically and without limitation any  
12 personal injury or directly related claims, that could be brought by any other individual or  
13 organization. Defendants hereby release each Plaintiff from and against any claims arising out  
14 of each Plaintiff's notices and their filing or prosecution of this action. Each Party respectively  
15 waives any right to appeal or other review of this Consent Judgment, except as expressly  
16 provided in this Consent Judgment, and Plaintiff Buckland expressly agrees that she will dismiss  
17 the pending appeal as to the Defendants, which was initiated by notice of appeal filed on August  
18 17, 2006.

19 **6. Covenant Not To Sue.** The Parties covenant and agree that with regard to those matters  
20 that the Parties have herein released and that are described above, neither Plaintiffs nor  
21 Defendants will ever institute a lawsuit or administrative proceedings against the other, nor shall  
22 Plaintiffs or Defendants assert any claim of any nature against any person or entity hereby  
23 released with regard to any such matters which have been released. However, nothing in this  
24 paragraph shall be interpreted to preclude enforcement of this Consent Judgment pursuant to  
25 paragraph 7 below.

26 **7. Enforcement of Consent Judgment.** Any Party may, by noticed motion or order to  
27 show cause before the Superior Court of Los Angeles, enforce this Consent Judgment. To  
28 enforce this Consent Judgment, any Party must first give written notice of any violation of this

1 Consent Judgment alleged to have occurred to the Party alleged to be in violation. The Parties  
2 shall meet and confer in good faith and attempt to resolve the alleged violation. If a resolution is  
3 not reached within thirty (30) days of the date of the notice, the aggrieved Party may move the  
4 Court to hear and resolve the dispute. The prevailing Party in any proceeding brought to enforce  
5 this Consent Judgment shall be entitled to recover from the other Party the prevailing Party's  
6 reasonable attorneys' fees and costs incurred in the investigation and prosecution of such an  
7 enforcement proceeding.

8 **8. Application of Consent Judgment.** Paragraphs 3, 5 and 6 of this Consent Judgment  
9 shall apply to, be binding upon and inure to the benefit of the Parties, Ms. Buckland and the  
10 CWLC, their divisions, subdivisions, subsidiaries, affiliates, successors, predecessors and  
11 assigns, and the directors, officers, employees, legal counsel, consultants and agents of each of  
12 them, as applicable, and will inure to the benefit of the Parties' parent companies, all suppliers,  
13 distributors, wholesalers, retailers and contract manufacturers, and all of their respective  
14 directors, officers, employees, legal counsel, consultants and agents.

15 **9. Modification/Termination of Consent Judgment.** This Consent Judgment may be  
16 modified or terminated upon written agreement of Defendants and Plaintiffs, with approval of  
17 the Court, or upon noticed motion for good cause shown. However, the Parties shall meet and  
18 confer in good faith and attempt to mutually agree upon any modification prior to the filing of  
19 any motion. The Parties acknowledge that new toxicological information or exposure  
20 assessments concerning hazardous substances and testing methodologies are continuously  
21 becoming available, and that statutory and regulatory standards applicable to the Products may  
22 evolve in the future, either of which may establish good cause for modification of this Consent  
23 Judgment. The burden of proof in any such motion shall be on the moving party to establish  
24 such good cause. The prevailing Party in any such motion shall be entitled to recover from the  
25 other Party the prevailing Party's reasonable attorneys' fees and costs incurred in the preparation  
26 and prosecution of such a motion.

27 **10. Governing Law.** This Consent Judgment shall be governed by, and construed in  
28 accordance with, the laws of the State of California.



1 **11. Entire Agreement.** The Parties declare and represent that no promise, inducement or  
2 other agreement has been made conferring any benefit upon any party except those contained  
3 herein and that this Consent Judgment contains the entire agreement pertaining to the subject  
4 matter hereof. This Consent Judgment supersedes any prior or contemporaneous negotiations,  
5 representations, agreements and understandings of the Parties with respect to such matters,  
6 whether written or oral. Parol evidence shall be inadmissible to show agreement by, between or  
7 among the Parties to any term or condition contrary to or in addition to the terms and conditions  
8 contained in this Consent Judgment. The Parties acknowledge that each has not relied on any  
9 promise, representation or warranty, expressed or implied, not contained in this Consent  
10 Judgment except with regard to that certain declaration executed under penalty of perjury by the  
11 Defendants providing information that induced Ms. Buckland and CWLC to enter into the  
12 financial terms of this Consent Judgment, which declaration may be used solely as evidence in  
13 any future enforcement proceeding brought pursuant to Paragraph 7 above.

14 **12. Challenges.** Subject to their rights to apply for a modification of this Consent Judgment  
15 for good cause shown under Paragraph 9 hereof, the Parties agree that they, individually or  
16 collectively, will not seek to challenge or to have determined invalid, void or unenforceable any  
17 provision of this Consent Judgment or this Consent Judgment itself. The Parties understand that  
18 this Consent Judgment contains the relinquishment of legal rights and each Party has, as each  
19 has deemed appropriate, sought the advice of legal counsel, which each of the Parties has  
20 encouraged the other to seek. Further, no Party has reposed trust or confidence in any other  
21 Party so as to create a fiduciary, agency or confidential relationship.

22 **13. Construction.** This Consent Judgment has been jointly negotiated and drafted. The  
23 language of this Consent Judgment shall be construed as a whole according to its fair meaning  
24 and not strictly for or against any Party.

25 **14. Authority to Stipulate to Consent Judgment.** Each signatory to this Consent Judgment  
26 represents and warrants that each signatory has all requisite power, authority and legal right  
27 necessary to execute and deliver this Consent Judgment and to perform and carry out the  
28 transactions contemplated by this Consent Judgment. Each signatory to this Consent Judgment

1 represents that each has been duly authorized to execute this Consent Judgment. No other or  
2 further authorization or approval from any person will be required for the validity and  
3 enforceability of the provisions of this Consent Judgment, except entry by the Court.

4 **15. Cooperation and Further Assurances.** The Parties will execute such other documents  
5 and take such other actions as may be necessary to further the purposes and fulfill the terms of  
6 this Consent Judgment.

7 **16. Counterparts.** This Consent Judgment may be executed in counterparts and has the  
8 same force and effect as if all the signatures were obtained in one document.

9 **17. Notices.**

10 **17.1** All correspondence and notices required by this Consent Judgment to Ms.  
11 Buckland shall be sent to:

12 Katherine Lee Buckland, Esq.  
13 California Women's Law Center  
14 6300 Wilshire Boulevard, Suite 980  
15 Los Angeles, CA 90048  
16 Tel: (323) 951-1041  
17 Fax: (323) 951-9870  
18 [katie@cwlc.org](mailto:katie@cwlc.org)

With a copy to:  
19 Roger Lane Carrick, Esq.  
20 The Carrick Law Group, P.C.  
21 350 S. Grand Avenue, Suite 2930  
22 Los Angeles, CA 90071-3406  
23 Tel: (213) 346-7930  
24 Fax: (213) 346-7931  
25 E-mail: [roger@carricklawgroup.com](mailto:roger@carricklawgroup.com)

18 **17.2** All correspondence and notices required by this Consent Judgment to CWLC shall  
19 be sent to:

20 Katherine Lee Buckland  
21 Executive Director  
22 California Women's Law Center  
23 6300 Wilshire Boulevard, Suite 980  
24 Los Angeles, CA 90048  
25 Tel: (323) 951-1041  
26 Fax: (323) 951-9870  
27 [katie@cwlc.org](mailto:katie@cwlc.org)

With a copy to:  
28 Roger Lane Carrick  
The Carrick Law Group, P.C.  
350 S. Grand Avenue, Suite 2930  
Los Angeles, CA 90071-3406  
Tel: (213) 346-7930  
Fax: (213) 346-7931  
E-mail: [roger@carricklawgroup.com](mailto:roger@carricklawgroup.com)

26 ///

27 ///

28 ///



1 **21. Non-Interference in Settlement Approval Process.** The Parties will cooperate, as well  
 2 as use their respective best efforts, to secure the Attorney General's approval of this Consent  
 3 Judgment, and not to seek his disapproval of any portion of this Consent Judgment.

4 **IT IS SO STIPULATED.**

5 Date: March 22, 2007.

KATHERINE LEE BUCKLAND, an individual

6  
 7 By:   
 8 \_\_\_\_\_  
 KATHERINE LEE BUCKLAND


9 Date: March 22, 2007

CALIFORNIA WOMEN'S LAW CENTER

10  
 11 By:   
 12 \_\_\_\_\_  
 Executive Director

13 Date: March 16, 2007

14 LIFE-FLO HEALTH CARE PRODUCTS, INC.  
 15 (including ALLVIA INTEGRATIVE  
 16 PHARMACEUTICALS, INC., and SAYGE  
 17 BIOSCIENCES, LLC.)

18 By:   
 19 \_\_\_\_\_  
 John Rose  
 20 CEO

28

1 **FINDINGS AND ORDER**

2 1. In light of the findings below, and based upon the Court’s review of the proposed  
3 stipulated Consent Judgment executed by the Plaintiffs and Defendants, and the papers filed in  
4 support of this Motion to Enter the stipulated Consent Judgment, in a manner consistent with  
5 Code of Civil Procedure §664.6, the Court finds that this Consent Judgment is just, and serves  
6 and will serve the public interest.

7 2. The Court finds that the warnings that are or may be required in Section 3 of the  
8 stipulated Consent Judgment in this matter regarding the sale of certain products by Defendant  
9 comply with the provisions of Health & Safety Code §§25249.6 and 25249.7(f)(4)(A).

10 3. In the stipulated Consent Judgment in this matter, the Parties’ agreement in  
11 Section 4 of the Consent Judgment that no civil penalties are warranted is in accord with the  
12 criteria set forth in Health & Safety Code §25249.7(b) (2) and (f) (4) (C), in that payments  
13 totaling \$15,000 in the form of “in lieu of damages or penalties” are to be made by the  
14 Defendant to Plaintiff California Women’s Law Center (“CWLC”). The Court finds that CWLC  
15 has committed to use this financial relief in conformity with Proposition 65’s overall goals as  
16 well as its own non-profit articles of incorporation to address the litigation’s public health issue  
17 of protecting women’s health through CWLC’s programs, which include but are not limited to  
18 projects addressing public health, domestic violence, reproductive rights, and physical fitness  
19 issues.

20 4. The Consent Judgment is hereby adopted as the ORDER and JUDGMENT of this  
21 Court.

22 **IT IS SO ORDERED, ADJUDGED, AND DECREED.**

23 DATED: \_\_\_\_\_  
24

25 \_\_\_\_\_  
26 **ROBERT L. HESS**  
27 **JUDGE OF THE SUPERIOR COURT**  
28